share_log

康希诺生物ACYW135群脑膜炎球菌多糖结合疫苗曼海欣®首批产品获得批签发

The first batch of CANSINOBIO ACYW135 meningococcal polysaccharide conjugate vaccine Manhaixin ®was issued in batch.

Breakings ·  Jun 29, 2022 20:15
ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 vector) of CANSINOBIO Co., Ltd.-Manhaixin ®(hereinafter referred to as: tetravalent meningococcal conjugate vaccine), the first batch of products obtained the "Biological products batch issuance Certificate" issued by the State Drug Administration, and officially listed on the domestic market. Manhaixin ®is the first ACYW135 group meningococcal conjugate vaccine in China, which fills the gap of lack of high-end vaccine products in this field. The successful launch of this product will bring more comprehensive and high-quality protection to Chinese children.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment